Heidelberg Pharma AG (HPHA.DE)
EUR 2.7
(-1.82%)
EUR 2.7
(-1.82%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -37.6 Million EUR | 42.45% |
| 2022 | -65.34 Million EUR | -1555.37% |
| 2021 | 4.49 Million EUR | 193.95% |
| 2020 | -4.77 Million EUR | 51.64% |
| 2019 | -9.88 Million EUR | 49.16% |
| 2018 | -19.44 Million EUR | 36.01% |
| 2017 | -30.38 Million EUR | -3576.39% |
| 2016 | -826.38 Thousand EUR | 36.71% |
| 2015 | -1.3 Million EUR | 38.39% |
| 2014 | -2.11 Million EUR | 65.63% |
| 2013 | -6.16 Million EUR | 69.75% |
| 2012 | -20.38 Million EUR | -368.32% |
| 2011 | 7.59 Million EUR | 503.02% |
| 2010 | -1.88 Million EUR | 44.73% |
| 2009 | -3.41 Million EUR | 71.86% |
| 2008 | -12.12 Million EUR | 35.51% |
| 2007 | -18.79 Million EUR | 66.86% |
| 2006 | -56.7 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -27.41 Million EUR | 27.11% |
| 2024 Q2 | -21.25 Million EUR | 22.48% |
| 2024 Q3 | -15.27 Million EUR | -71.34% |
| 2023 Q3 | -44.91 Million EUR | 21.39% |
| 2023 Q2 | -57.13 Million EUR | 11.88% |
| 2023 Q1 | -64.84 Million EUR | 0.78% |
| 2023 FY | -37.6 Million EUR | 42.45% |
| 2023 Q4 | -37.6 Million EUR | 16.27% |
| 2022 Q4 | -65.34 Million EUR | -532.33% |
| 2022 Q3 | -10.33 Million EUR | 42.18% |
| 2022 FY | -65.34 Million EUR | -1555.37% |
| 2022 Q1 | -4.37 Million EUR | -197.34% |
| 2022 Q2 | -17.87 Million EUR | -308.89% |
| 2021 Q1 | -2.73 Million EUR | 42.74% |
| 2021 Q4 | 4.49 Million EUR | 133.34% |
| 2021 Q2 | -777.06 Thousand EUR | 71.61% |
| 2021 FY | 4.49 Million EUR | 193.95% |
| 2021 Q3 | -13.46 Million EUR | -1633.43% |
| 2020 Q4 | -4.77 Million EUR | 46.9% |
| 2020 Q1 | -4.64 Million EUR | 53.0% |
| 2020 FY | -4.77 Million EUR | 51.64% |
| 2020 Q2 | -14.89 Million EUR | -220.62% |
| 2020 Q3 | -9 Million EUR | 39.57% |
| 2019 Q2 | -13.1 Million EUR | 18.42% |
| 2019 FY | -9.88 Million EUR | 49.16% |
| 2019 Q1 | -16.06 Million EUR | 17.34% |
| 2019 Q3 | -12.7 Million EUR | 3.05% |
| 2019 Q4 | -9.88 Million EUR | 22.23% |
| 2018 FY | -19.44 Million EUR | 36.01% |
| 2018 Q4 | -19.44 Million EUR | 14.39% |
| 2018 Q2 | -25.53 Million EUR | 5.95% |
| 2018 Q3 | -22.7 Million EUR | 11.07% |
| 2018 Q1 | -27.15 Million EUR | 10.63% |
| 2017 FY | -30.38 Million EUR | -3576.39% |
| 2017 Q4 | -30.38 Million EUR | -4867.84% |
| 2017 Q3 | -611.55 Thousand EUR | 86.76% |
| 2017 Q2 | -4.61 Million EUR | -484.97% |
| 2017 Q1 | 1.19 Million EUR | 245.17% |
| 2016 Q1 | -2.3 Million EUR | -76.51% |
| 2016 FY | -826.38 Thousand EUR | 36.71% |
| 2016 Q4 | -826.38 Thousand EUR | 74.72% |
| 2016 Q3 | -3.26 Million EUR | 36.42% |
| 2016 Q2 | -5.14 Million EUR | -123.12% |
| 2015 FY | -1.3 Million EUR | 38.39% |
| 2015 Q1 | -1.35 Million EUR | 36.04% |
| 2015 Q2 | -4.09 Million EUR | -202.06% |
| 2015 Q3 | -3.06 Million EUR | 25.1% |
| 2015 Q4 | -1.3 Million EUR | 57.43% |
| 2014 Q1 | -2.94 Million EUR | 52.21% |
| 2014 Q3 | -2.75 Million EUR | -1260.88% |
| 2014 Q2 | -202.35 Thousand EUR | 93.13% |
| 2014 FY | -2.11 Million EUR | 65.63% |
| 2014 Q4 | -2.11 Million EUR | 23.04% |
| 2013 Q3 | -7.09 Million EUR | 29.79% |
| 2013 Q2 | -10.1 Million EUR | 32.05% |
| 2013 Q1 | -14.87 Million EUR | 27.04% |
| 2013 FY | -6.16 Million EUR | 69.75% |
| 2013 Q4 | -6.16 Million EUR | 13.09% |
| 2012 Q3 | -28.3 Million EUR | -463.9% |
| 2012 FY | -20.38 Million EUR | -368.32% |
| 2012 Q1 | 2.69 Million EUR | -64.59% |
| 2012 Q2 | 7.77 Million EUR | 189.1% |
| 2012 Q4 | -20.38 Million EUR | 27.98% |
| 2011 Q3 | -7.59 Million EUR | 42.65% |
| 2011 Q1 | -4.49 Million EUR | -138.61% |
| 2011 FY | 7.59 Million EUR | 503.02% |
| 2011 Q4 | 7.59 Million EUR | 200.02% |
| 2011 Q2 | -13.24 Million EUR | -194.44% |
| 2010 Q1 | -10.65 Million EUR | -212.47% |
| 2010 FY | -1.88 Million EUR | 44.73% |
| 2010 Q4 | -1.88 Million EUR | 75.22% |
| 2010 Q3 | -7.6 Million EUR | -142.21% |
| 2010 Q2 | -3.14 Million EUR | 70.53% |
| 2009 FY | -3.41 Million EUR | 71.86% |
| 2009 Q4 | -3.41 Million EUR | 0.0% |
| 2008 FY | -12.12 Million EUR | 35.51% |
| 2007 FY | -18.79 Million EUR | 66.86% |
| 2006 FY | -56.7 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| BioNTech SE | -11.44 Billion EUR | 99.671% |
| CureVac N.V. | -360.92 Million EUR | 89.58% |
| Biotest Aktiengesellschaft | 571.3 Million EUR | 106.583% |
| Biotest Aktiengesellschaft | 571.3 Million EUR | 106.583% |
| BRAIN Biotech AG | -693 Thousand EUR | -5326.774% |
| Formycon AG | 2.45 Million EUR | 1634.376% |
| Medigene AG | -5.72 Million EUR | -557.015% |